1985.09 – 1989.06 郑州大学化学系，本科
1989.09 – 1992.06 郑州大学化学系有机化学专业，硕士
2001.09 – 2005.06 复旦大学药学院药物化学专业，在职博士，获理学博士学位
1992.07 – 1999.03 郑州大学化学系，助教、讲师（1995年）
1993.09 – 1994.09 日本京都龍谷大学，访问学者
1999.04 – 现在 复旦大学药学院药物化学教研室，副教授（2000年）、教授（2010年）
2006.01 – 现在 兼任药学实验教学中心主任
2011.10 – 现在 上海市药学会药物化学专业委员会委员
2019年 上海市育才奖
2015年 “宝钢优秀教师奖”
2013年 上海市教学成果二等奖（第二完成人）
2012年 复旦大学“创先争优·教书育人”优秀共产党员称号
活性天然产物的合成、结构改造与成药性研究
1. Peng, Y.; Shi, Z.; Liang, Y.; Ding, K.;* Wang, Y.* Targeting the tumor microenvironment by an enzyme-responsive prodrug of tubulin destabilizer for triple-negative breast cancer therapy with high safety, Eur. J. Med. Chem. 2022, 236, 114344.
2. Tang, H.; Liang, Y.; Shen, H.; Cai, S.; Yu, M.; Fan, H.; Ding, K.;* Wang, Y.* Discovery of a 2,6-Diarylpyridine-Based Hydroxamic Acid Derivative as Novel Histone Deacetylase 8 and Tubulin Dual Inhibitor for the Treatment of Neuroblastoma, Bioorg. Chem. 2022, 128, 106112.
3. Tang, H.; Liang, Y.; Cheng, J.; Ding, K.*; Wang, Y.* Bifunctional Chiral Selenium-Containing 1,4-Diarylazetidin-2-ones with Potent Antitumor Activities by Disrupting Tubulin Polymerization and Inducing Reactive Oxygen Species Production, Eur. J. Med. Chem. 2021, 221, 113531.
4. Lin, S.; Liang, Y.; Cheng, J.; Pan, F.; Wang, Y.* Novel Diaryl-2H-azirines: Antitumor Hybrids for Dual-targeting Tubulin and DNA, Eur. J. Med. Chem. 2021, 214, 113256.
5. Liang, Y.; Zhang, M.; Zhou, P.; Liu, M.;* Li, J.;* Wang, Y.* Design, Synthesis and Antitumor Evaluation of Novel Chiral Diaryl Substituted Azetidin-2-one Derivatives as Tubulin Polymerization Inhibitors, Bioorg. Chem. 2021, 115, 105239.
6. Hao, E.-J.; Li, G.-X.; Liang, Y.-R.; Xie, M.-S.; Wang, D.-C.; Jiang, X.-H.; Cheng, J.-Y.; Shi, Z.-X.; Wang, Y.*; Guo, H.-M.* Design, Synthesis and Activity Evaluation of Novel Acyclic Nucleosides as Potential Anticancer Agents in Vitro and in Vivo, J. Med. Chem. 2021, 64, 2077-2109.
7. Tang, H.; Cheng, J.; Liang, Y.; Wang, Y.* Discovery of a Chiral Fluorinated Azetidin-2-one as a Tubulin Polymerisation Inhibitor with Potent Antitumour Efficacy, Eur. J. Med. Chem. 2020, 197, 112323.
8. Liu, M.; Liang, Y.; Zhu, Z.; Wang, J.; Cheng, X.; Cheng, J.; Xu, B.; Li, R.; Liu, X.*; Wang, Y.* Discovery of Novel Aryl Carboxamide Derivatives as Hypoxia-Inducible Factor (HIF) 1α Signaling Inhibitors with Potent Activities of Anticancer Metastasis, J. Med. Chem. 2019, 62, 9299-9314.
9. Gao, F.; Liang, Y.; Zhou, P.; Cheng, J.; Ding, K.*; Wang, Y.* Design, Synthesis, Antitumor Activities and Biological Studies of Novel Diaryl Substituted Fused Heterocycles as Dual Ligands Targeting Tubulin and Katanin, Eur. J. Med. Chem. 2019, 178, 177-194.
10. Zhou, P.; Liang, Y.; Zhang, H.; Jiang, H.; Feng, K.; Xu, P.; Wang, J.; Wang, X.; Ding, K.*; Luo, C.*; Liu, M.*; Wang, Y.* Design, Synthesis, Biological Evaluation and Cocrystal Structures with Tubulin of Chiral β-Lactam Bridged Combretastatin A-4 Analogues as Potent Antitumor Agents, Eur. J. Med. Chem. 2018, 144, 817-842.
11. Zhang M.; Liang, Y.-R.; Li, H.; Liu, M.-M.*; Wang, Y.* Design, Synthesis, and Biological Evaluation of Hydantoin Bridged Analogues of Combretastatin A-4 as Potential Anticancer Agents, Bioorg. Med. Chem. 2017, 25, 6623-6634.
12. Sheng, X.; Jia, X.-Y.; Tang, F.; Wang, Y.*; Hou, A.-J.* The Total Synthesis of (±)-Sanggenol F, Tetrahedron 2017, 73, 3485-3491.
13. Zhou, P.; Liu, Y.; Zhou, L.; Zhu, K.; Feng, K.; Zhang, H.; Liang, Y.; Jiang, H.; Luo, C.*; Liu, M.*; Wang, Y.* Potent Anti-tumor Activities and Structure Basis of the Chiral β-Lactam Bridged Analogue of Combretastatin A-4 Binding to Tubulin, J. Med. Chem. 2016, 59, 10329-10334.
